Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1Phase 1 1

Status

Recruiting 4Active not recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Thoracic 7

Conditions

Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 1

Interventions

Carboplatin 351pembrolizumab 327Pemetrexed 249Cisplatin 221Paclitaxel 149Nivolumab 139durvalumab 134Docetaxel 112osimertinib 111atezolizumab 107Specimen Handling 91Radiotherapy 89Drug Therapy 87Magnetic Resonance Spectroscopy 78Etoposide 78Radiosurgery 74Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 43Cetuximab 35Taxes 34Injections 33Biopsy 33Standard of Care 32Platinum 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
aumolertinib × Thoracic × 1 year × Clear all
NCT04841811 2026-05-22

APPROACH

Guangdong Association of Clinical Trials

Phase 3 Active not recruiting
192 enrolled
Thoracic

Lung Neoplasms

NCT06300424 2026-04-29

NEOVADE

Guangdong Provincial People's Hospital

Phase 2 Active not recruiting
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06613633 2026-04-29

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Fudan University

Completed
4,000 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07183189 2026-04-14

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
576 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07130916 2025-08-19

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06417008 2025-08-01

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Hansoh BioMedical R&D Company

Phase 2/3 Recruiting
1,080 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06951464 2025-07-23

A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Sichuan University

Phase 2 Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡